SCHEDULE 13G/A 0001124140 XXXXXXXX LIVE 1 Ordinary shares, no par value 01/09/2026 0001872529 MDxHealth SA B5950S113 CAP Business Center Zone Industrielle des Hauts-Sarts Herstal C9 4040 Rule 13d-1(c) Genomic Health, Inc. DE 6441171.00 0.00 6441171.00 0.00 6441171.00 N 12.0 CO Row 11 is calculated based on 49,497,334 ordinary shares issued and outstanding as described in the Issuer's Registration Statement on Form F-3 filed with the U.S. Securities and Exchange Commission on December 29, 2025. Exact Sciences Corporation DE 0.00 6441171.00 0.00 6441171.00 6441171.00 N 12.0 CO Row 11 is calculated based on 49,497,334 ordinary shares issued and outstanding as described in the Issuer's Registration Statement on Form F-3 filed with the U.S. Securities and Exchange Commission on December 29, 2025. MDxHealth SA CAP Business Center, Zone Industrielle des Hauts-Sarts, Herstal, C9, 4040 (a) Genomic Health, Inc. (b) Exact Sciences Corporation (a) The business address of Genomic Health, Inc. is 5505 Endeavor Lane, Madison, WI 53719 (b) The business address of Exact Sciences Corporation is 5505 Endeavor Lane, Madison, WI 53719 (a) Genomic Health, Inc. - Delaware (b) Exact Sciences Corporation - Delaware Y As of the date hereof, Genomic Health, Inc. owns 2,441,171 Ordinary Shares and warrants/contractual rights to purchase an additional 4,000,000 Ordinary Shares of the Issuer. Genomic Health, Inc. is a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences Corporation, through the ownership described herein may be deemed to beneficially own the Ordinary Shares directly owned by Genomic Health, Inc. See responses to Item 11 on the attached cover pages. See responses to Item 5 on the attached cover pages. See responses to Item 6 on the attached cover pages. See responses to Item 7 on the attached cover pages. See responses to Item 8 on the attached cover pages. Y N Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. See Exhibit 99.1 for Joint Filing Agreement, dated as of January 16, 2026, by and among the Reporting Persons Genomic Health, Inc. /s/ James Herriott 01/16/2026 Exact Sciences Corporation /s/ James Herriott 01/16/2026